DBV Technologies (DBV) Q3 2025 earnings summary

Executive summary

• Focused on advancing Viaskin Peanut patch for peanut allergy in children, with two parallel BLA submissions planned for toddlers (1–3 years) and children (4–7 years).

• Ongoing pivotal Phase 3 VITESSE study in 4–7-year-olds; topline results expected Q4 2025.

• Regulatory alignment with FDA on Accelerated Approval pathway for toddlers and BLA submission strategy for both age groups.

• Updated manufacturing agreement with SANOFI to secure supply for potential commercial launch.

• Ended Q3 2025 with $69.8 million in cash and cash equivalents, extending runway into Q3 2026.

Financial highlights

• Cash and cash equivalents were $69.8 million as of September 30, 2025, up from $32.5 million at December 31, 2024.

• Net loss for Q3 2025 was $33.2 million, compared to $30.4 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $102.1 million, up from $90.9 million in the prior year period.

• Operating expenses rose to $107.0 million for the nine months, up from $96.4 million year-over-year, mainly due to the COMFORT Toddlers study.

• Operating income for Q3 2025 was $2.8 million, primarily from research tax credits.

• Financing activities in 2025 provided $117.1 million in net cash inflow for the nine months ended September 30, 2025.

Outlook and guidance

• Cash runway is estimated to fund operations into Q3 2026, but not for a full 12 months from the report date, raising substantial doubt about going concern.

• Management is actively pursuing additional financing options, including ATM equity offerings and potential warrant exercises.

• BLA submission for Viaskin Peanut patch in 4–7-year-olds planned for H1 2026; potential product launch could be accelerated by one year, pending FDA approval.

• Topline results from the VITESSE Phase 3 study expected in Q4 2025, which could accelerate warrant exercises.